Merck’s Erbitux is being recommended for routine NHS use to treat recurrent or metastatic squamous cell cancer of the head and neck.
News
NICE turns down AZ’ Faslodex for breast cancer
It is looking unlikely that AstraZeneca’s breast cancer drug Faslodex will be routinely funded on the NHS to delay growth of a specific type of breast cancer, after cost regulators concluded that its benefit over existing therapies has not been shown at this time.
Heptares doses first subject in Alzheimer’s drug trial
London, UK-based Heptares Therapeutics says the first healthy subject has now been dosed with its first-in-class, selective muscarinic M4 receptor agonist HTL0016878 in a Phase I clinical study.
Wales sees 400% leap in patients waiting more than a year for surgery
The number of patients waiting for more than a year for surgical treatment on the NHS in Wales has rocketed more than 400 percent in four years.
US clears new antibiotic for UTIs
The US Food and Drug Administration has approved a new antibacterial drug to treat patients with complicated urinary tract infections (UTI).
PharmaTimes Marketer of the Year closing for entries today
The prestigious PharmaTimes Marketer of the Year competition closes for entries today. It only takes a few seconds to fill out the online entry form and then you don’t need to do anything else until the day of the competition.
Why winning PharmaTimes Marketer of the Year was one of the biggest highlights of my career
The prestigious PharmaTimes Marketer of the Year competition closes for entries and nominations at midnight tomorrow. If you haven’t entered yet, don’t panic! It takes less than a minute to fill out the online entry form – and you don’t have to do anything else until the day of the competition.
NHS will pay £80bn for PFI contracts
Companies holding Private Finance Initiative contracts to build and run NHS hospitals have made £831 million in pre-tax profits over the past six years, money which could have reduced the deficit in NHS hospitals by a quarter over the period, finds a new report by The Centre for Health and the Public Interest.
CMA clears Birmingham hospitals merger
The Competition and Markets Authority has cleared a merger between Heart of England NHS Foundation Trust (HEFT) and University Hospitals Birmingham NHS Foundation Trust (UHB).
Final NHS green light for Allergan’s IBS-D drug
Allergan’s Truberzi has become the first treatment for irritable bowel syndrome with diarrhoea (IBS-D) to be reviewed and recommended by the National Institute for Health and Care Excellence for use on the NHS in England and Wales.
FDA approves Teva’s Austedo for tardive dyskinesia
Teva’s Austedo is now the first and only therapy approved in the US to treat both tardive dyskinesia and chorea associated with Huntington’s disease.
Novartis’ Kymriah first cell therapy to win US green light
Novartis’ Kymriah has become the first ever CAR-T cell therapy to win approval in the US, bringing paediatric and young adult patients with B-cell acute lymphoblastic leukaemia a novel treatment approach.
Report lays out new strategy for UK life sciences
Industry-led plans to breathe new life into the UK’s £64-billion life sciences sector have now been unveiled, alongside details of £160 million in government funding to fuel progress in the field.
Boehringer’s Humira biosimilar wins US green light
US regulators have approved Boehringer Ingelheim’s Cyltezo, a biosimilar to AbbVie’s Humira, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases.
Pfizer, Avillion file for Bosulif expansion
Pfizer and Avillion have filed applications on both sides of the Atlantic seeking to expand the treatment scope of chronic myeloid leukaemia therapy Bosulif.
